Hugo

Underground production celebrated at Oyu Tolgoi

Retrieved on: 
Monday, March 13, 2023
Natural Resources, Other Natural Resources, Mining, Minerals, Economic development, Treaty of friendship and alliance between the Government of Mongolia and Tibet, Tax, Copper, Vision 2050 (Rwanda), Politics of Mongolia, Workforce, Hugo, Gobi Desert, Competent person, Mineral resource estimation, Rio Tinto, Person, Partnership, Uranium mining, Oyu Tolgoi mine

The Prime Minister of Mongolia, Luvsannamsrain Oyun-Erdene, today joined Rio Tinto Chief Executive Jakob Stausholm 1.3 kilometres underground to celebrate the commencement of underground production from the Oyu Tolgoi copper mine in the Gobi Desert.

Key Points: 
  • The Prime Minister of Mongolia, Luvsannamsrain Oyun-Erdene, today joined Rio Tinto Chief Executive Jakob Stausholm 1.3 kilometres underground to celebrate the commencement of underground production from the Oyu Tolgoi copper mine in the Gobi Desert.
  • This was followed by a ceremony with Oyu Tolgoi employees and leaders, Government of Mongolia representatives, Oyu Tolgoi Board members and local suppliers to mark this important milestone towards Oyu Tolgoi ramping up to become one of the world’s leading copper suppliers.
  • Since the agreement between the Government of Mongolia and Rio Tinto in January 2022 to reset the relationship and move the Oyu Tolgoi underground project forward, 30 drawbells have been blasted and copper is now being produced from the underground mine.
  • The start of underground production at Oyu Tolgoi demonstrates our ability to work together with investors in a sustainable manner and become a trusted partner.

Galapagos to present new data from long-term extension study of filgotinib in ulcerative colitis at annual ECCO congress 2023

Retrieved on: 
Monday, February 27, 2023
JAK, Safety, Cate, Doctor of Philosophy, Hugo, FRCPC, Filgotinib, CET, JAK1, Research, Anemia, Patient, LTE, Abstract, Quality of life (healthcare), Ulcerative colitis, RA, Rheumatoid arthritis, ECCO, European, Congress, Western University, Epidemiology, IBD, Galapagos NV, Euronext, Pharmaceutical industry, Biostatistics, MD, UC, Galápagos Islands, Immunology

A number of abstracts will present analyses from the SELECTION program with filgotinib.

Key Points: 
  • A number of abstracts will present analyses from the SELECTION program with filgotinib.
  • Additionally, Galapagos will present pooled data from five Phase 2/3 trials, and two long-term extension trials of filgotinib designed to further understand the safety profile of filgotinib in UC and rheumatoid arthritis (RA).
  • “We are excited to present data from multiple studies of filgotinib in UC, including results from the SELECTIONLTE study, which has been selected amongst the top 11 oral abstracts at ECCO,” said Daniele D’Ambrosio, MD, PhD, Therapeutic Area Head, of Immunology, at Galapagos.
  • Amongst subjects who completed the study, the reduction in mean pMCS in SELECTION was maintained up to LTE Week 144.

Rio Tinto delivers underlying EBITDA of $26.3 billion and total dividends of 492 US cents per share

Retrieved on: 
Wednesday, February 22, 2023
Professional Services, Natural Resources, Mining, Minerals, Finance, Lithium, EBITDA, Safety, Juukan Gorge, Climate change, Female, Trust, Workplace, Hugo, Yinjibarndi language, Policy, ESG, JV, TRQ, Heart, Pekuakamiulnuatsh First Nation, SPS, James Wedgwood Drawbell, Acquisition, Turquoise Hill Resources, AGR, International Financial Reporting Standards, Indigenous peoples, APM, Environment, PKKP, Panel, Oyu Tolgoi mine, Agreement, Fatality, Rio Tinto, Kurrama people, International, Movement, Paraburdoo, Western Australia, Injury, Person, Rhodes, Heads of Agreement (1981), Rincon, CSP, Cryptocurrency, Renewable energy, Iron ore

Free cash flow1 of $9.0 billion included capital expenditure of $6.8 billion, which decreased 9% as we commissioned our current programme of Pilbara replacement projects, notably Gudai-Darri.

Key Points: 
  • Free cash flow1 of $9.0 billion included capital expenditure of $6.8 billion, which decreased 9% as we commissioned our current programme of Pilbara replacement projects, notably Gudai-Darri.
  • $26.3 billion underlying EBITDA1 was 30% below 2021, with an underlying EBITDA margin1 of 45%.
  • $13.3 billion underlying earnings1 (underlying EPS1 of 819.6 US cents) were 38% below 2021.
  • $8.0 billion full-year dividend, equivalent to 492 US cents per share.

Tamisha M. Chestnut Joins The WNET Group as Vice President, Human Resources

Retrieved on: 
Wednesday, February 1, 2023
BlackRock, Mitchell & Titus, IBM, Equity, Trustee, Human resources, Hampton University, Abyssinian Baptist Church, Mercy College, PBS, Hugo, The, Morgan Stanley, The Ursuline School, Management, Nursing, Chestnut

NEW YORK, Feb. 1, 2023 /PRNewswire/ -- The WNET Group, parent company of America's flagship PBS station THIRTEEN, has named Tamisha M. Chestnut Vice President, Human Resources, reporting to the president and CEO.

Key Points: 
  • NEW YORK, Feb. 1, 2023 /PRNewswire/ -- The WNET Group, parent company of America's flagship PBS station THIRTEEN, has named Tamisha M. Chestnut Vice President, Human Resources, reporting to the president and CEO.
  • She succeeds Charlene Shapiro, who will retire after 14 years as Vice President at The WNET Group.
  • Prior to that, from 2009-2011, she was vice president, human resources and diversity at BlackRock, the world's largest asset manager based in New York City.
  • I look forward to supporting my new colleagues, advancing innovative human capital planning, and promoting an inclusive workplace culture," said Chestnut.

IRS Free File Now Open for 2023-The Free File Alliance Offers Taxpayers Free Industry-Leading Tax Software

Retrieved on: 
Monday, January 16, 2023
IOS, Identity theft, Tax, IRS, Free File, Security awareness, Tablet, English, Free File Alliance, Revenue stream, Free, Software, AGI, Hugo, Android, TaxSlayer, Security, Internal Revenue Service, Online shopping, Health insurance

WASHINGTON, Jan. 16, 2023 /PRNewswire/ -- Taxpayers can get a head start on preparing their tax returns as Free federal tax preparation and e-filing software is now available at www.IRS.gov/FreeFile to all Americans with a 2022 adjusted gross income (AGI) of $73,000 or less. Powered by The Free File Alliance, a coalition of 7 industry-leading tax software companies partnered with the Internal Revenue Service (IRS), the Free File program gives eligible taxpayers free access to the industry's most innovative and secure tax software in order to easily prepare and e-file their federal tax returns.

Key Points: 
  • Powered by The Free File Alliance , a coalition of 7 industry-leading tax software companies partnered with the Internal Revenue Service (IRS), the Free File program gives eligible taxpayers free access to the industry's most innovative and secure tax software in order to easily prepare and e-file their federal tax returns.
  • With the tax filing season not officially opening until January 23rd, eligible taxpayers can get a head start on their taxes by e-filing utilizing the Free File software.
  • Taxpayers can also use their smart phones or tablets to electronically prepare and file their federal and state tax returns through IRS Free File.
  • Free File Fillable Forms allows taxpayers who are familiar with tax law and need no preparation assistance to complete and file their federal income tax electronically.

Flare Launches Layer 1 Oracle Network

Retrieved on: 
Sunday, January 22, 2023
Kucoin, Upbit, FLR, API, OKX, Acquisition, Decentralized finance, High-integrity pressure protection system, Safety, Blockchain, State, Internet, UTC, History, Hugo, Cryptocurrency, Binance, Flare, Kraken

The airdrop is a significant milestone for Flare as developers can now start to take advantage of Flare’s EVM and native data acquisition protocols, the State Connector and Flare Time Series Oracle.

Key Points: 
  • The airdrop is a significant milestone for Flare as developers can now start to take advantage of Flare’s EVM and native data acquisition protocols, the State Connector and Flare Time Series Oracle.
  • Hugo Philion, CEO & Co-founder of Flare said,
    “For the blockchain industry to flourish, we need more useful decentralized applications.
  • This offers the most powerful class of data on the network and enables more cross-chain solutions to be built.
  • The Flare Time Series Oracle (FTSO) utilizes the network structure to deliver highly decentralized prices and data series to dapps on Flare without relying on centralized data providers.

Pharnext strengthens its ties with Néovacs to secure the next steps in its development

Retrieved on: 
Sunday, January 22, 2023
Communication, Regulatory News Service, CET, Medtech, Research, CFO, Biotechnology, Patient, Degenerative disease, Confidentiality, Investment, FDA, Therapy, Sciences Po, EMA, Verney-Carron, Marketing, Neurodegeneration, Hugo, Security (finance), Pharmaceutical industry, Health insurance, Management, Euronext

Under the terms of the agreement, Néovacs could become a reference shareholder of Pharnext as of January 1, 2024.

Key Points: 
  • Under the terms of the agreement, Néovacs could become a reference shareholder of Pharnext as of January 1, 2024.
  • This new financing agreement is a partial or total complement to the OCEANE-BSA financing granted by Global Tech Opportunities 13 ("GTO 13").
  • However, Néovacs, through the trust managing its financing contract with Pharnext, has agreed to subscribe to the €1 million tranche scheduled for late December.
  • It was unbelievable that the Company would find itself in difficulty and that is why Néovacs decided to support it.

Pharnext strengthens its Senior Leadership Team with the appointment of Scott Johnson as VP, Head of Quality

Retrieved on: 
Sunday, January 22, 2023
General counsel, Warner Chilcott, CMC, Regulatory News Service, Master of Pharmacy, CET, United States Department of the Navy, Pharmacovigilance, MD, Johnson & Johnson, Pfizer, Good laboratory practice, Good manufacturing practice, Capsule, Eastern University, Sri Lanka, NDA, BA, Good clinical laboratory practice, Patient, Organization, Regulatory affairs, SLT, Therapy, Charcot–Marie–Tooth disease, Cellectis, Eastern University, Master of Science, Quality assurance, Tablet, Scott, Bachelor of Science, Gan, Doctor of Philosophy, Neurodegeneration, Hugo, Management, Pharmaceutical industry, Medical device, Sanofi, Quality

Pharnext strengthens its Senior Leadership Team with the appointment of Scott Johnson as VP, Head of Quality

Key Points: 
  • Pharnext strengthens its Senior Leadership Team with the appointment of Scott Johnson as VP, Head of Quality
    Dissemination of a French Regulatory News, transmitted by EQS Group.
  • Pharnext strengthens its Senior Leadership Team with the appointment of Scott Johnson as VP, Head of Quality
    PARIS, France, January 4th, 2023, 08:30 am CET – Pharnext SA (FR001400BV89 - ALPHA) (the “Company”), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, today announces the appointment of Scott Johnson as VP, Head of Quality.
  • Prior to Oyster, Scott served as Director, Quality Assurance at Lupin Pharmaceuticals where he had overall responsibility for quality and compliance.
  • Hugo Brugière, Chairman and Chief Executive Officer of Pharnext, commented: “I look forward to working with Scott and am delighted to welcome him to the Pharnext Senior Leadership Team.

Canada Laparoscopy Devices Market Report 2022: Analysis and Forecasts 2021-2031 - Rising Regulatory Approvals for Robotic Systems - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 22, 2022
Surgery, Health, Medical Devices, Medtronic, Health Canada, Scholly, COVID-19, Risk, Johnson & Johnson, Acquisition, Growth, Benchmarking, Intuitive Surgical, Laparoscopy, Ethicon Inc., Robotics, General surgery, Hugo, Medical device, Animal, Pharmaceutical industry, Dentistry

The "Canada Laparoscopy Devices Market: Focus on Product, Application, and End User - Analysis and Forecast, 2022-2031" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Canada Laparoscopy Devices Market: Focus on Product, Application, and End User - Analysis and Forecast, 2022-2031" report has been added to ResearchAndMarkets.com's offering.
  • The COVID-19 pandemic has impacted practically all sectors and social functions worldwide, including the Canada laparoscopy devices market.
  • COVID-19 led to a decline in the Canada laparoscopy devices market, as elective and surgical procedures were stopped during the lockdown.
  • The conventional laparoscopy devices segment holds the larger share in the Canada laparoscopy devices market at $350.6 million compared to the robotic-assisted laparoscopy devices segment which is valued at $41.5 million in the year 2021.

Medtronic announces first patient enrolled in U.S. clinical trial for Hugo™ robotic-assisted surgery system

Retrieved on: 
Thursday, December 15, 2022
Security (finance), Urology, Investigational device exemption, Nephrectomy, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Duke University Hospital, Diagnosis, Adoption of electronic medical records in U.S. hospitals, Partnership, Hugo, Patient, Sale, Hospital, Swedish Health Services, NYSE, Disease, RAS, FDA, Pain, Sofie (surgical robot), Clinical trial, URO, Goldfarb, Safety, Gynaecology, Health, General surgery, Dentistry, Medical device, Medtronic, Expansion

DUBLIN, Dec. 15, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global healthcare technology leader, today announced the first patient enrolled in the Expand URO U.S. clinical trial for the Hugo™ robotic-assisted surgery (RAS) system. The robotic-assisted prostatectomy procedure was performed by Dr. Michael R. Abern at Duke University Hospital in Durham, N.C.

Key Points: 
  • "Robotic-assisted surgery provides many benefits within my specialty of urology, and I'm proud to have performed the first U.S. clinical trial case with the Medtronic Hugo RAS system."
  • The Expand URO clinical trial is being conducted pursuant to an Investigational Device Exemption from the U.S. Food and Drug Administration (FDA).
  • "4
    The Hugo RAS system, combined with Touch Surgery Enterprise, offers a smart, digitally enabled surgical experience.
  • Regulatory requirements and status in individual countries and regions will determine market availability of the Hugo RAS system and approved indications.